Measles is still an important infection in many parts of the world. Until recently, the good vaccination coverage in the general population in Europe and USA reduced the risk for outbreaks and thereby the risk for transfer to stem cell transplantation (SCT) recipients. However, during the last few years, the vaccination rates of children in many countries have decreased. Recently, a large epidemic occurred in Italy and smaller outbreaks have been reported from several countries. Many patients will become seronegative to measles during an extended follow-up after SCT. 1, 2 This is important since occasional severe and fatal measles infections have been reported in SCT recipients. 3, 4 During a recent large outbreak in Brazil, one of eight patients with measles developed interstitial pneumonia but all survived. 2 New technologies have been introduced including an increasing use of unrelated donors, the use of peripheral stem cell grafts, and the use of reduced intensity conditioning regimens. The aim of this study was therefore to assess the influence of these new techniques on the risk for becoming vulnerable to measles after allogeneic SCT.
Patients and methods
In total, 395 consecutive measles seropositive patients transplanted with allogeneic grafts at Huddinge University Hospital from 1980 to 2002, who had a disease-free survival of at least 1 year after SCT were included in the analysis. Patient characteristics are shown in Table 1 . The median follow-up is 4 years (1-20) after transplantation.
The transplant procedures have been published previously. The conditioning regimens have varied over the years. The most common regimens for patients with malignancies have been cyclophosphamide 60 mg/kg for 2 days and total-body irradiation either 10 Gy given as a single fraction or 4 Â 3 Gy, busulfan 4 mg/kg for 4 days and cyclosphosphamide 60 mg/kg for 2 days. Patients with aplastic anemia have received cyclophosphamide 50 mg/kg Â 4 during the last decade together with ATG. Patients with metabolic disorders were treated with busulfan 4 mg/kg for 4 days and cyclophosphamide 50 mg/kg for 4 days. Reduced intensity regimens have been fludarabine 30 mg/m 2 for 5 days together with busulfan 4 mg/kg for 2 days or fludarabine 30 mg/m 2 for x days or TBI 2 Gy.
The majority of the patients receiving grafts from unrelated or HLA-mismatched family donors received ATG. GVHD prophylaxis was given either with methotrexate, cyclosporine or the combination of cyclosporine and methotrexate. [5] [6] [7] A few patients have received T-cell reduced grafts.
Acute and chronic graft-versus-host disease (GVHD) was defined according to published definitions. Treatment with 2 mg/kg of prednisolone was initiated at stage I acute GVHD. The most used therapy for chronic GVHD was the combination of prednisolone and cyclosporine A.
Measles serology
Measles antibodies were determined by ELISA. Since many old samples were not available, samples were analyzed in pairs rather than all samples from the same patient together in the same assay. The result of each sample has been defined to be either negative, doubtfully protective immunity, or positive. We have used the term doubtfully protective immunity since a substantial proportion of in particular children have been vaccinated at 2 years after SCT and it is likely that these patients would have become seronegative as well with a longer follow-up.
Measles vaccination
Vaccination could be given at 2 years after transplantation if they did not have chronic GVHD or ongoing immunosuppression. 8, 9 Most children have been vaccinated, but only few of the adults have been vaccinated. The indications for vaccination in the adults have been seronegativity in a patient either working with children, having young children in the household, or travel to areas where measles is still endemic.
Statistics
For univariate analysis and multivariate analysis, Cox proportional hazards regression was used. In the models, patient age was introduced as a continuous variable. Since we did not have information about donor age on all unrelated donors, it, was assumed to be 425 years in those where this information was lacking and therefore donor age was handled as a dichotomous variable (o or 425 years). Other factors included in univariate analysis were vaccination of the patient before transplantation, donor type (unrelated/mismatched vs HLA-identical sibling), conditioning regimen (reduced vs conventional), acute GVHD (0-I vs II-IV), stem cell source (PBSC vs bone marrow), stage of disease (early vs late), TBI (yes vs no), and chronic GVHD (yes vs no). The possible impact of nonmyeloablative conditioning regimens was analyzed with the Kaplan-Meier technique and the log-rank test. To compare antibody titers at 2 years after SCT, log 10 values of the ELISA titers were used with no immunity given the numerical value of 10. The titers were then compared by Student's t-test.
Results
The likelihood to have become seronegative at 2, 5, and 10 years after SCT was 23, 41, and 52%, respectively. The corresponding figures for the likelihood to have low and possibly not protective antibody levels were 38, 62, and 78%, respectively.
Risk factor analysis of risk factors for seronegativity
Univariate. In univariate analysis, patient age was the strongest risk factor for loss of immunity to measles so that younger patients were more likely to become seronegative (HR 1.03; 1.02-1.04; Po0.0001). Also to have been vaccinated pre-transplant rather than having had natural measles disease was significantly correlated to becoming seronegative (HR 2.3; 1.7-3.0; Po0.0001; Figure 1 ). Other Probability of being seropositive to measles 
Risk factor analysis for weak and doubtfully protective immunity
Univariate. Similar to the situation for seronegativity, patient age, previous measles vaccination, and donor age were significant risk factors for having doubtfully protective immunity.
Multivariate. Two multivariate models were constructed. The first included patient age. In this model, lower patient age (HR 1.06; 1.05-1.07; P ¼ 0.002) and having received a graft of peripheral stem cells (HR 1.7; 1.1-2.5; P ¼ 0.01) were significant risk factors while donor age was not. The second model included previous measles vaccination instead of patient age. In this model, previous measles vaccination (HR 2.1; 1.4-2.9; Po0.0001) was the only significant risk factor. The HR for peripheral blood stem cell graft was 1.4 (0.94-2.0; P ¼ 0.11).
Antibody levels at 2 years after SCT
The antibody titers at 2 years after SCT were compared in patients with previous measles infection or vaccination. Patients who had had a natural measles infection had higher antibody titers than patients who had been vaccinated (2.7 vs 2.2 log10; P ¼ 0.0005). Antibody titers in the two groups (vaccinated vs measles infection) were thereafter analyzed by other transplant factors (acute and chronic GVHD, type of conditioning, type of stem cells, type of donor). No factor significantly influenced the antibody titers in either of the groups.
Effects of reduced conditioning
Owing to a shorter follow-up of patients having received nonmyeloablative regimens, we performed an analysis censored at 2 years after SCT comparing the different intensity regimens. Patients transplanted with a reduced intensity regimen had a probability at 2 years after SCT of 14% to be seronegative, while the risk was 26% in patients receiving myeloablative conditioning regimens (P ¼ NS). Since most patients receiving reduced conditioning had experienced a natural measles infection; we split the analysis based on vaccination status. There was no difference in the probabilities to be seronegative in patients having experienced a natural measles infection at 2 years after SCT between the groups receiving different intensity conditioning regimens (19 vs 20%; P ¼ NS) while the number of patients having received a nonmyeloablative transplant and having been previously vaccinated to measles was too low to analyze separately.
Discussion
We have previously studied the long-term immune status to measles in a large cohort of allogeneic SCT recipients. 1 The main finding of that study was that patients having previously been vaccinated against measles were much more likely to become seronegative during follow-up than patients having experienced a natural measles infection. That study was performed almost entirely on patients having undergone HLA-identical sibling transplantation with bone marrow as the stem cell source and with myeloablative conditioning. During the last decade, other transplant modalities have been introduced. More than half our patients are transplanted from unrelated donors 6,10 and more than half of our patients receive peripheral stem cells rather than bone marrow grafts. 11, 12 More recently, nonmyeloablative conditioning has been introduced and is now used in many SCT patients. 13 Therefore, we wanted to repeat our previous study and analyze the impact of these new transplant modalities on the likelihood to become seronegative and to lose protective immunity against measles.
Similar to our previous study, pre-transplant vaccination to measles and lower patient age were the most important risk factors for losing immunity to measles. 1 The most important factor was previous immunization rather than age although these two factors are strongly correlated since the measles vaccination was introduced in Sweden as well as in many other countries in the 1970s and subsequently measles virus almost entirely ceased to circulate in society.
14 Donor age was significant in univariate analysis but not in multivariate analysis presumably due to the frequently similar ages of donors and recipients.
Acute GVHD grades II-IV had an impact on the likelihood of becoming seronegative while chronic GVHD was not. Of the 'new' transplant factors, only the use of peripheral stem cell grafts impacted on the likelihood to retain immunity to measles. A bit surprising, the direction of the effect was such that patients receiving peripheral stem cell grafts were more likely to have a weak immunity to measles. The reason for this trend is unclear. The number of transferred nucleated cells including B cells is higher in patients receiving peripheral blood stem cell grafts although considering the likely precursor frequency for an individual antigen such as measles, is likely to be low. Patients receiving peripheral stem cell grafts are more likely to develop chronic GVHD. However, chronic GVHD did not influence the likelihood of remaining immune to measles.
Reduced intensity conditioning regimens have been associated with a better short-term immune reconstitution although very limited long-term data on B-cell function have been presented. Since the aim, also in patients receiving reduced intensity conditioning transplants, is to replace patient' hematopoiesis with donor, the recipient memory B cells and plasma cells specific for measles should be depleted by the donor graft. This could possibly result in a better short-term specific immunity but no difference long-term. Maris et al 15 reported that the number of B cells was higher at 80 days after SCT in patients receiving nonmyeloablative compared to myeloblative SCT, but the antibody levels were similar and there was in fact a tendency for lower memory B-cell counts in patients conditioned with nonmyeloablative regimens. D'Sa et al 16 reported a delayed recovery of CD19 þ B-cells after nonmyeloablative conditioning with a regimen containing alemtuzumab. Although the number of patients having received reduced intensity transplants was low in our study, the data suggest no difference between the two groups especially since all patients receiving reduced intensity transplants were adults previously having experienced a natural measles infection.
Why is information regarding measles immunity important? First, it can be a marker of B-cell immunity to other antigens. Second, measles may be a severe and possibly fatal infection in immunocompromised patients 2, 3, [17] [18] [19] and recently the vaccine coverage of the normal population is decreasing and outbreaks have been reported. [20] [21] [22] Since with time, more and more patients will have been vaccinated rather than having experienced a natural measles infection, an increasing number of patients is likely to be vulnerable in an outbreak situation. Fortunately, no patient in our study cohort developed clinical measles although a few patients had unexplained measles antibody titer increases during follow-up indicating either subclinical measles infection or exposure to vaccinated children excreting the vaccine strain of measles virus.
The available measles vaccines are live and attenuated and are not recommended for use in immunocompromised patients since the development of serious side effects is possible. 23 Thus, immunization can be considered only in allogeneic SCT patients without chronic GVHD or ongoing immunosuppression. Although during a recent epidemic in Brazil, patients were immunized at 1 year after SCT and preliminary data suggest that this could be done safely, 2 the current recommendations by both the CDC and the European Group for Blood and Marrow Transplantation are not to vaccinate earlier than 2 years after SCT. 9, 24 We believe it is important to assess immunity regularly during the follow-up after SCT in particular in children and young adults and for patients residing in or traveling to geographical areas where measles is endemic. Vaccination should be considered for seronegative SCT patients.
